BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Sarcomas AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
471 results:

  • 1. Correlations between the modification patterns mediated by pyroptosis-related genes, tumor microenvironment, and immunotherapy in soft tissue sarcoma.
    Cai Y; Meng J; Qiu Y; Huang X; Du H; Yao J
    Medicine (Baltimore); 2024 May; 103(20):e38173. PubMed ID: 38758862
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
    Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
    Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
    Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
    Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. New advances in the treatment of chondrosarcoma under the PD-1/pd-l1 pathway.
    Yin J; Ren P
    J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
    Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Case report: Pathological complete response induced by immunochemotherapy in a case of Pulmonary Sarcomatoid Carcinoma staged IIIA-N2.
    Guo Y; Liu X; Tang H; Qiu Z; Ma F; Hu A; Liu C; Wang Y
    Front Immunol; 2024; 15():1374270. PubMed ID: 38650938
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis.
    Ji R; Wang Y; Pan D; Han J; Wang Y; Zheng S; Zhao W; Li X; Han C; Zhang L
    Cancer Lett; 2024 Jun; 591():216893. PubMed ID: 38636892
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Radiotherapy combined with anti-PD-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and pd-l1: a case report.
    Deng S; Yang X; He L; Zhang Q; Zhao C; Meng H
    J Cardiothorac Surg; 2024 Apr; 19(1):194. PubMed ID: 38594687
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Teacher-student collaborated multiple instance learning for pan-cancer pdl1 expression prediction from histopathology slides.
    Jin D; Liang S; Shmatko A; Arnold A; Horst D; Grünewald TGP; Gerstung M; Bai X
    Nat Commun; 2024 Apr; 15(1):3063. PubMed ID: 38594278
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
    Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
    Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. CPPs-modified chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma.
    Cao J; Zhu C; Cao Z; Ke X
    Int J Biol Macromol; 2024 May; 267(Pt 2):130915. PubMed ID: 38561118
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Visual analysis of bone malignancies immunotherapy: A bibliometric analysis from 2010 to 2023.
    Shen K; Yang L; Ke S; Gao W
    Medicine (Baltimore); 2024 Mar; 103(13):e37269. PubMed ID: 38552042
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Primary pulmonary histiocytic sarcoma with high pd-l1 expression benefited from immunotherapy: A case report and bioinformatic analysis.
    Lin Y; Cao Q; Hong A; Liang X
    Clin Respir J; 2024 Mar; 18(3):e13741. PubMed ID: 38450981
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. pd-l1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
    Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
    Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma Treatment
    Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
    Toulmonde M; Guegan JP; Spalato-Ceruso M; Peyraud F; Kind M; Vanhersecke L; Le Loarer F; Perret R; Cantarel C; Bellera C; Bessede A; Italiano A
    Mol Cancer; 2024 Feb; 23(1):38. PubMed ID: 38378555
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Treatment and prognostic implications of strong pd-l1 expression in primary hepatic sarcomatoid carcinoma.
    Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
    Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma.
    Tang S; Wang Y; Luo R; Fang R; Liu Y; Xiang H; Ran P; Tong Y; Sun M; Tan S; Huang W; Huang J; Lv J; Xu N; Yao Z; Zhang Q; Xu Z; Yue X; Yu Z; Akesu S; Ding Y; Xu C; Lu W; Zhou Y; Hou Y; Ding C
    Nat Commun; 2024 Feb; 15(1):1381. PubMed ID: 38360860
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRAS
    Lin P; Cheng W; Qi X; Zhang P; Xiong J; Li J
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338834
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
    Zhou P; Fu Y; Tang Y; Jiang L; Wang W
    Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 24.